Spectrum Pharmaceuticals (NASDAQ:SPPI)
This company will either get its stuff together or it won't. Manage the risks, CYA.
Cell Therapeutics (NASDAQ:CTIC) has nothing remotely close to being approved. Yet, CTIC maintains a market cap of $290 M. SPPI maintains a market cap of $239 million after yesterday's ridiculous sell-off.
Before overreacting to every headline, investors should try to keep things in perspective.
My bet, SPPI will get there eventually.
Disclosure: Long SPPI.